|
US5879680A
(en)
|
1987-12-23 |
1999-03-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cloned DNA for synthesizing unique glucocerebrosidase
|
|
US6521225B1
(en)
|
1996-09-06 |
2003-02-18 |
Chiron Corporation |
AAV vectors
|
|
ES2340230T3
(es)
|
1998-11-10 |
2010-05-31 |
University Of North Carolina At Chapel Hill |
Vectores viricos y sus procedimientos de preparacion y administracion.
|
|
US6696272B1
(en)
|
1999-06-02 |
2004-02-24 |
Hsc Research & Development Limited Partnership |
Products and methods for gaucher disease therapy
|
|
GB0009887D0
(en)
|
2000-04-20 |
2000-06-07 |
Btg Int Ltd |
Cytotoxic agents
|
|
CA2406743A1
(en)
|
2000-04-28 |
2001-11-08 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
|
|
AU2001290984A1
(en)
|
2000-09-18 |
2002-04-02 |
Genzyme Corporation |
Expression vectors containing hybrid ubiquitin promoters
|
|
US7232670B2
(en)
|
2001-09-28 |
2007-06-19 |
St. Jude Children's Research Hospital |
Targeting proteins to cells expressing mannose receptors via expression in insect cells
|
|
US20030133924A1
(en)
|
2001-12-21 |
2003-07-17 |
Novazyme Pharmaceuticals, Inc. |
Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease
|
|
AU2003221733A1
(en)
|
2002-04-17 |
2003-11-03 |
University Of Florida Research Foundation, Inc. |
Improved raav vectors
|
|
ES2562490T3
(es)
|
2003-05-01 |
2016-03-04 |
Genzyme Corporation |
Terapia génica para trastornos neurometabólicos
|
|
WO2006036465A2
(en)
|
2004-09-03 |
2006-04-06 |
University Of Florida |
Compositions and methods for treating cystic fibrosis
|
|
WO2006039253A2
(en)
|
2004-09-29 |
2006-04-13 |
Children's Memorial Hospital |
Sirna-mediated gene silencing of alpha synuclein
|
|
CN101541172A
(zh)
*
|
2005-06-08 |
2009-09-23 |
阿米库斯治疗学公司 |
溶酶体酶编码基因突变相关的cns紊乱的治疗
|
|
ES2385679T3
(es)
|
2006-08-24 |
2012-07-30 |
Virovek, Inc. |
Expresión de células de insecto de genes con marcos de lectura abiertos superpuestos, métodos y composiciones de éstos
|
|
US8962273B2
(en)
|
2007-05-11 |
2015-02-24 |
Genzyme Corporation |
Methods of producing a secreted protein
|
|
EP2154969B1
(en)
|
2007-05-16 |
2015-11-18 |
The Brigham and Women's Hospital, Inc. |
Treatment of synucleinopathies
|
|
WO2009079399A2
(en)
|
2007-12-14 |
2009-06-25 |
Alnylam Pharmaceuticals, Inc. |
Method of treating neurodegenerative disease
|
|
WO2010129791A1
(en)
|
2009-05-06 |
2010-11-11 |
University Of Medicine And Dentistry Of New Jersey |
Rna targeting in alpha-synucleinopathies
|
|
EP2826860B1
(en)
|
2010-04-23 |
2018-08-22 |
University of Massachusetts |
CNS targeting AAV vectors and methods of use thereof
|
|
WO2012027558A2
(en)
*
|
2010-08-25 |
2012-03-01 |
The Trustees Of Columbia University In The City Of New York |
OPTIMIZED miRNA CONSTRUCTS
|
|
WO2012027713A2
(en)
|
2010-08-26 |
2012-03-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of snca
|
|
EP2634253B1
(en)
|
2010-10-27 |
2016-05-11 |
Jichi Medical University |
Adeno-associated virus virions for transferring genes into neural cells
|
|
US20150352185A1
(en)
|
2010-11-16 |
2015-12-10 |
Denis G. Kay |
Method for increasing neprilysin expression and activity
|
|
CA2835707C
(en)
|
2011-05-09 |
2019-02-26 |
Eip Pharma, Llc |
Compositions and methods for treating alzheimer's disease
|
|
JP2016503405A
(ja)
*
|
2012-11-05 |
2016-02-04 |
ジェンザイム・コーポレーション |
タンパク質症を処置するための組成物および方法
|
|
CN105377039A
(zh)
|
2013-05-15 |
2016-03-02 |
明尼苏达大学董事会 |
腺相关病毒介导的基因向中枢神经系统转移
|
|
US9347107B2
(en)
|
2013-05-23 |
2016-05-24 |
Norman Z Lai |
Vector containing multiple nucleotide sequences for the expression of enzymes
|
|
CN120174012A
(zh)
|
2013-10-24 |
2025-06-20 |
优尼科Ip有限公司 |
用于基因治疗神经疾病的aav-5假型载体
|
|
IL248102B
(en)
*
|
2014-05-02 |
2022-07-01 |
Genzyme Corp |
aav vectors for gene therapy of the central nervous system and retina
|
|
WO2016081927A2
(en)
|
2014-11-21 |
2016-05-26 |
University Of Florida Research Foundation, Inc. |
Genome-modified recombinant adeno-associated virus vectors
|
|
US20170035860A1
(en)
|
2015-04-02 |
2017-02-09 |
Alexander C. Flynn |
Compositions and methods for treatment of neurogenerative diseases
|
|
JP2015180203A
(ja)
*
|
2015-04-17 |
2015-10-15 |
ザ スクリプス リサーチ インスティテュート |
タンパク質生産の増強のためのｍＲＮＡの一次構造の再操作
|
|
EP3292206B8
(en)
|
2015-05-07 |
2022-02-09 |
Takeda Pharmaceutical Company Limited |
Glucocerebrosidase gene therapy for parkinson's disease
|
|
EP3091087A1
(en)
|
2015-05-08 |
2016-11-09 |
Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol |
Method for in vitro diagnosis of synucleinopathies using alpha-synuclein gene transcripts
|
|
HK1256341A1
(zh)
|
2015-05-15 |
2019-09-20 |
明尼苏达大学董事会 |
用於治疗性递送到中枢神经系统的腺相关物
|
|
WO2017075338A2
(en)
|
2015-10-29 |
2017-05-04 |
Voyager Therapeutics, Inc. |
Delivery of central nervous system targeting polynucleotides
|
|
RU2021102893A
(ru)
|
2015-11-05 |
2021-03-03 |
Бамбу Терапьютикс, Инк. |
Модифицированные гены атаксии фридрейха и векторы для генной терапии
|
|
WO2017136536A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
PL3411484T3
(pl)
|
2016-02-05 |
2024-02-19 |
Emory University |
Wstrzykiwanie jednoniciowego lub samokomplementarnego wirusa adenosatelitarnego 9 do płynu mózgowego
|
|
WO2017151884A1
(en)
|
2016-03-02 |
2017-09-08 |
The Children's Hospital Of Philadelphia |
Therapy for frontotemporal dementia
|
|
KR20230079511A
(ko)
|
2016-04-21 |
2023-06-07 |
바이로베크 인코포레이티드 |
곤충 세포에서의 aav 생산, 및 이를 위한 방법 및 조성물
|
|
BR112020006671A2
(pt)
|
2017-10-03 |
2020-12-01 |
Prevail Therapeutics, Inc. |
terapias genéticas para distúrbios lisossômicos
|
|
KR102709597B1
(ko)
|
2017-10-03 |
2024-09-26 |
프리베일 테라퓨틱스, 인크. |
리소좀 장애를 위한 유전자 요법
|
|
EP3692075A4
(en)
|
2017-10-03 |
2022-02-09 |
Prevail Therapeutics, Inc. |
GENE THERAPIES FOR LYSOSOMAL DISEASES
|
|
AU2018354195A1
(en)
|
2017-10-23 |
2020-06-04 |
Prevail Therapeutics, Inc. |
Gene therapies for neurodegenerative disease
|
|
CA3134841A1
(en)
|
2019-04-10 |
2020-10-15 |
Prevail Therapeutics, Inc. |
Gene therapies for lysosomal disorders
|
|
US20220211871A1
(en)
|
2019-04-10 |
2022-07-07 |
Prevail Therapeutics, Inc. |
Gene therapies for lysosomal disorders
|